USE OF HLA CLASS 1 SOLUBLE MOLECULES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS USEFUL FOR INHIBITING ANGIOGENESIS

摘要

The invention relates to the use of a HLA class 1 soluble molecule or a nucleic acid molecule comprising a polynucleotide sequence that codes for a HLA class 1 molecule for the preparation of pharmaceutical compositions that are intended to inhibit angiogenesis or to detect angiogenic sites. More specifically, the invention relates to the use of HLA-G1 molecules or HLA-B7 molecules for the treatment of pathologies including cancer, diabetic retinopathies, rheumatoid polyarthritis, chronic rejection of transplants, such as cornea or kidney, or acute rejection observed in xenotransplantations, angiomas, angiosarcomas, in particular Castleman's disease or Kaposi's sarcoma.